Subscribe to this journal
Advanced Search
Share
September - October 2010 Utilization of hyperestrogenic therapies in systemic lupus erythematosus
Journal Information
Previous article | Next article
Vol. 6. Issue 5.
Pages 264-267 (September - October 2010)
Export reference
Share
Share
Print
Download PDF
More article options
Statistics
Vol. 6. Issue 5.
Pages 264-267 (September - October 2010)
DOI: 10.1016/S2173-5743(10)70061-7
Full text access
Utilization of hyperestrogenic therapies in systemic lupus erythematosus
Utilización de terapias hiperestrogénicas en el lupus eritematoso sistémico
Visits
5251
Download PDF
Jaime Calvo-Alén
Corresponding author
jcalvo@hsll.scsalud.es

Corresponding author.
, Cristina Mata, Elena Aurrecoechea
Sección de Reumatología, Hospital General Sierrallana, IFIMAV, Universidad de Cantabria, Cantabria, Spain
This item has received
5251 Visits
Article information
Statistics
Abstract

The use of treatments that increase oestrogen levels has usually been deemed risky in lupus patients. Past studies about the utilisation of oral contraceptive drugs and hormone replacement therapy (HRT) have shown contradictory results. More recently, prospective studies about this issue suggest that either oral anticontraceptives or HRT can be used in patients with stable disease without special risk for increments in clinical activity. Neither has an association with the development of arterial or venous thrombosis been observed. However, in this respect, several methodological limitations preclude establishing definitive conclusions.

Regarding the use of assisted reproduction techniques in lupus patients, only retrospective data are available. Overall they indicate that the real risk of disease exacerbation is quite low, the flares being generally mild when these procedures are performed in patients with stable disease.

Keywords:
Systemic lupus erythematosus
Estrogen
Assisted fertilization
Resumen

La utilización de tratamientos que aumenten los niveles estrogénicos ha sido considerada clásicamente de riesgo en pacientes lúpicos. Estudios relativamente antiguos sobre la utilización de anticonceptivos orales y de tratamiento hormonal sustitutivo han proporcionado resultados contradictorios o inconsistentes. Más recientemente, estudios prospectivos sobre esta problemática sugieren que tanto los anticonceptivos como el tratamiento hormonal sustitutivo pueden ser utilizados en pacientes con enfermedad estable sin riesgo de un aumento en la actividad clínica de ésta. Tampoco se ha observado una asociación al desarrollo de complicaciones tromboembólicas arteriales y/o venosas. Aunque, a este respecto, determinaciones y limitaciones metodológicas imposibilitan el establecer valoraciones definitivas sobre esta problemática.

Con respecto a la utilización de técnicas de fertilización asistida en pacientes lúpicas, todos los datos de que se disponen son de tipo retrospectivo. Globalmente considerados, estos estudios indican que el riesgo real de reagudización de la enfermedad es relativamente bajo y que, en general, no son agudizaciones graves, siempre y cuando estas técnicas se realicen en pacientes con enfermedad estable.

Palabras clave:
Lupus eritematoso sistémico
Estrógenos
Fertilización asistida
Full text is only aviable in PDF
References
[1.]
H. Carlsten, A. Tarkowski.
Histocompatibility complex gene products and exposure to oestrogen: Two independent disease accelerating factors in murine lupus.
Scand J Immunol, 38 (1993), pp. 341-347
Medline
[2.]
J.R. Roubinian, N. Talal, J.S. Greenspan, J.R. Goodman, P.K. Siiteri.
Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice.
J Exp Med, 147 (1978), pp. 1568-1583
Medline
[3.]
J. Sánchez-Guerrero, E.W. Karlson, M.H. Liang, D.J. Hunter, F.E. Speizer, G.A. Colditz.
Past use of oral contraceptives and the risk of developing systemic lupus erythematosus.
Arthritis Rheum, 40 (1997), pp. 804-808
http://dx.doi.org/10.1002/1529-0131(199705)40:5<804::AID-ART4>3.0.CO;2-E | Medline
[4.]
J. Sánchez-Guerrero, M.H. Liang, E.W. Karlson, D.J. Hunter, G.A. Colditz.
Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus.
Ann Intern Med, 122 (1995), pp. 430-433
Medline
[5.]
R.G. Lahita, L. Bradlow, J. Fishman, H.G. Kunkel.
Estrogen metabolism in systemic lupus erythematosus: Patients and family members.
Arthritis Rheum, 25 (1982), pp. 843-846
Medline
[6.]
I.N. Bruce, C.A. Laskin.
Sex hormones in systemic lupus erythematosus: a controversy for modern times.
J Rheumatol, 24 (1997), pp. 1461-1463
Medline
[7.]
B. Pimstone.
Systemic lupus erythematosus exacerbated by oral contraceptives.
S Afr J Obstet Gynecol, 3 (1966), pp. 62-63
[8.]
T.A. Chapel, R.E. Burns.
Oral contraceptives and exacerbation of lupus erythematosus.
Am J Obstet Gynecol, 110 (1971), pp. 366-369
Medline
[9.]
R.L. Travers, G.R. Hughes.
Oral contraceptive therapy and systemic lupus erythematosus.
J Rheumatol, 5 (1978), pp. 448-451
Medline
[10.]
M. Garovich, C. Agudelo, E. Pisko.
Oral contraceptives and systemic lupus erythematosus.
Arthritis Rheum, 23 (1980), pp. 1396-1398
Medline
[11.]
F. Furukawa, T. Tachibana, S. Imamura, T. Tamura.
Oral contraceptive-induced lupus erythematosus in a Japanese woman.
J Dermatol, 18 (1991), pp. 56-58
Medline
[12.]
P. Jungers, M. Dougados, C. Pelissier, F. Kuttenn, F. Tron, P. Lesavre, et al.
Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus.
Arthritis Rheum, 25 (1982), pp. 618-623
Medline
[13.]
H.A. Julkunen.
Oral contraceptives in systemic lupus erythematosus: side-effects and influence on the activity of SLE.
Scand J Rheumatol, 20 (1991), pp. 427-433
Medline
[14.]
J.P. Buyon, K.C. Kalunian, M.L. Skovron, M. Petri, R. Lahita, J. Merrill, et al.
Can women with systemic lupus erythematosus safely use exogenous estrogens?.
J Clin Rheumatol, 1 (1995), pp. 205-212
Medline
[15.]
M. Petri, M.Y. Kim, K.C. Kalunian, J. Grossman, B.H. Hahn, L.R. Sammaritano, et al.
Combined oral contraceptives in women with systemic lupus erythematosus.
N Engl J Med, 353 (2005), pp. 2550-2558
http://dx.doi.org/10.1056/NEJMoa051135 | Medline
[16.]
J. Sánchez-Guerrero, A.G. Uribe, L. Jimánez-Santana, M. Mestanza-Peralta, P. Lara-Reyes, A.H. Seuc, et al.
A trial of contraceptive methods in women with systemic lupus erythematosus.
N Engl J Med, 353 (2005), pp. 2539-2549
http://dx.doi.org/10.1056/NEJMoa050817 | Medline
[17.]
C.C. Mok, C.S. Lau, C.T. Ho, R.W. Wong.
Do flares of systemic lupus erythematosus decline after menopause?.
Scand J Rheumatol, 28 (1999), pp. 357-362
Medline
[18.]
C.C. Mok, C.S. Lau, R.W. Wong.
Use of exogenous estrogens in systemic lupus erythematosus.
Semin Arthritis Rheum, 30 (2001), pp. 426-435
http://dx.doi.org/10.1053/sarh.2001.22498 | Medline
[19.]
J. Sánchez-Guerrero, A. Villegas, A. Mendoza-Fuentes, J. Romero-Díaz, G. Moreno-Coutino, M.C. Cravioto.
Disease activity during the premenopausal and postmenopausal periods in women with systemic lupus erythematosus.
Am J Med, 111 (2001), pp. 464-468
Medline
[20.]
M.B. Urowitz, D. Ibanez, D. Jerome, D.D. Gladman.
The effect of menopause on disease activity in systemic lupus erythematosus.
J Rheumatol, 33 (2006), pp. 2192-2198
Medline
[21.]
M. Fernández, J. Calvo-Alen, G.S. Alarcón, J.M. Roseman, H.M. Bastian, B.J. Fessler, et al.
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women.
Arthritis Rheum, 52 (2005), pp. 1655-1664
http://dx.doi.org/10.1002/art.21048 | Medline
[22.]
J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, M.L. Stefanick, et al.
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.
JAMA, 288 (2002), pp. 321-333
Medline
[23.]
S. Manzi, E.N. Meilahn, J.E. Rairie, C.G. Conte, T.A. Medsger, L. Jansen-McWilliams, et al.
Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study.
Am J Epidemiol, 145 (1997), pp. 408-415
Medline
[24.]
Y. Asanuma, A. Oeser, A.K. Shintani, E. Turner, N. Olsen, S. Fazio, et al.
Premature coronary-artery atherosclerosis in systemic lupus erythematosus.
N Engl J Med, 349 (2003), pp. 2407-2415
http://dx.doi.org/10.1056/NEJMoa035611 | Medline
[25.]
M.J. Roman, B.A. Shanker, A. Davis, M.D. Lockshin, L. Sammaritano, R. Simantov, et al.
Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus.
N Engl J Med, 349 (2003), pp. 2399-2406
http://dx.doi.org/10.1056/NEJMoa035471 | Medline
[26.]
N.K. Arden, M.E. Lloyd, T.D. Spector, G.R. Hughes.
Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE).
Lupus, 3 (1994), pp. 11-13
Medline
[27.]
S. Kreidstein, M.B. Urowitz, D.D. Gladman, J. Gough.
Hormone replacement therapy in systemic lupus erythematosus.
J Rheumatol, 24 (1997), pp. 2149-2152
Medline
[28.]
J.P. Buyon, M.A. Petri, M.Y. Kim, K.C. Kalunian, J. Grossman, B.H. Hahn, et al.
The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial.
Ann Intern Med, 142 (2005), pp. 953-962
Medline
[29.]
J. Sánchez-Guerrero, M. González-Pérez, M. Durand-Carbajal, P. Lara-Reyes, L. Jiménez-Santana, J. Romero-Díaz, et al.
Menopause hormonal therapy in women with systemic lupus erythematosus.
Arthritis Rheum, 56 (2007), pp. 3070-3079
http://dx.doi.org/10.1002/art.22855 | Medline
[30.]
M. Fernández, G. McGwin, A.M. Bertoli, J. Calvo-Alen, G.S. Alarcón.
Systemic lupus erythematosus in a multiethnic cohort (LUMINAXXXIX): relationship between hormone replacement therapy and disease activity over time.
Lupus, 15 (2006), pp. 621-622
Medline
[31.]
M. Fernández, J. Calvo-Alen, A.M. Bertoli, H.M. Bastian, B.J. Fessler, G. McGwin, et al.
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA L II): relationship between vascular events and the use of hormone replacement therapy in postmenopausal women.
J Clin Rheumatol, 13 (2007), pp. 261-265
http://dx.doi.org/10.1097/RHU.0b013e318156bbf5 | Medline
[32.]
C.C. Beerendonk, P.A. Van Dop, D.D. Braat, J.M. Merkus.
Ovarian hyperstimulation syndrome: facts and fallacies.
Obstet Gynecol Surv, 53 (1998), pp. 439-449
Medline
[33.]
A. Ben-Chetrit, E. Ben-Chetrit.
Systemic lupus erythematosus induced by ovulation induction treatment.
Arthritis Rheum, 37 (1994), pp. 1614-1617
Medline
[34.]
P. Casoli, B. Tumiati, G. La Sala.
Fatal exacerbation of systemic lupus erythematosus after induction of ovulation.
J Rheumatol, 24 (1997), pp. 1639-1640
Medline
[35.]
A. Benshushan, A. Shushan, O. Paltiel, N. Mordel, N. Laufer.
Ovulation induction with clomiphene citrate complicated by deep vein thrombosis.
Eur J Obstet Gynecol Reprod Biol, 62 (1995), pp. 261-262
Medline
[36.]
D.L. Huong, B. Wechsler, D. Vauthier-Brouzes, P. Duhaut, N. Costedoat, G. Lefebvre, et al.
Importance of planning ovulation induction therapy in systemic lupus erythematosus and antiphospholipid syndrome: a single center retrospective study of 21 cases and 114 cycles.
Semin Arthritis Rheum, 32 (2002), pp. 174-188
http://dx.doi.org/10.1053/sarh.2002.37212 | Medline
[37.]
N. Guballa, L. Sammaritano, S. Schwartzman, J. Buyon, M.D. Lockshin.
Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome.
Arthritis Rheum, 43 (2000), pp. 550-556
http://dx.doi.org/10.1002/1529-0131(200003)43:3<550::AID-ANR10>3.0.CO;2-Y | Medline
Copyright © 2010. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología

Subscribe to our newsletter

Special content about COVID-19
Publish in
Reumatología Clínica
Idiomas
Reumatología Clínica (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?